Login
$FHTX
$1.76 -$0.03 (1.68%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Adrian Gottschalk Also a director
Chief Executive Officer and Director (Class II)
50 Not stated Not stated $2,361,027
Ryan Maynard
Chief Financial Officer
56 Since 2026
this year
Not stated Not reported
Steven Bellon
Chief Scientific Officer
61 Since 2022
4 years
Not stated $1,199,455
Carlos Costa
Chief People Officer
53 Since 2022
4 years
2018 Not reported
Michael LaCascia
Chief Legal Officer
61 Since 2020
6 years
Not stated Not reported
Alfonso Quintás-Cardama
Chief Medical Officer
55 Since 2023
3 years
Not stated $1,133,965
Anna Rivkin
Chief Business Officer
52 Since 2024
2 years
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
10
serving now
Independent
0 of 1
stated in the proxy; 9 not stated
Average tenure
8.0 years
from year joined
Director Age On board Independent Committees Other public boards 2025 pay Source
Adrian Gottschalk
Not stated Not stated Not independent None stated None stated Paid as CEO
Douglas Cole
65 2015
11 years
Not stated
Compensation Committee
None stated $177,321
Balkrishan (Simba) Gill
62 2017
9 years
Not stated None stated None stated Not stated
B. Lynne Parshall
72 2022
4 years
Not stated None stated Cytokinetics, Inc. $151,754
Scott Biller
Not stated Not stated Not stated None stated None stated Not stated
Stuart Duty
Not stated Not stated Not stated
Audit Committee
None stated $194,669
Neil J. Gallagher
Not stated Not stated Not stated None stated None stated Not stated
Thomas J. Lynch, Jr.
Not stated Not stated Not stated None stated None stated $140,087
Michael Mendelsohn
Not stated Not stated Not stated None stated None stated $147,321
Ian F. Smith
Not stated Not stated Not stated None stated None stated $131,970

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

8 disclosed in the proxy filed Apr 30, 2026
Cigall Kadoch, Ph.D.
academic co-founder, former director and holder of more than 5% of our Common Stock
Amount not stated

Consulting agreement for advisory services on chromatin remodeling products, with a share grant and consulting fee.

Cigall Kadoch, Ph.D.
academic co-founder, former director and holder of more than 5% of our Common Stock
$0.2 million
2025 and 2024

Payments to Dr. Kadoch under the consulting agreement.

Eli Lilly and Company
5% or greater shareholder in the Company
Amount not stated

Strategic collaboration under the Lilly Collaboration Agreement, with a stock purchase of 4,000,000 shares at $20.00 per share and shared program costs.

Eli Lilly and Company
5% or greater shareholder in the Company
$8.2 million
2025

Payments by the Company to Lilly for 2025 under the collaboration.

BVF Partners, L.P.
holder of more than 5% of our common stock
Approximately $25 million
2026

Purchase of common stock and pre-funded warrants in the January 2026 equity offering.

Flagship Pioneering, Inc.
holder of more than 5% of our common stock
Approximately $15 million
2026

Purchase of pre-funded warrants in the January 2026 equity offering.

Deerfield Partners LP
holder of more than 5% of our common stock
Approximately $5 million
2026

Purchase of common stock in the January 2026 equity offering.

FMR LLC
holder of more than 5% of our common stock
$5 million
2026

Purchase of common stock in the January 2026 equity offering.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support